7.1 Immune Checkpoint Inhibitors & irAE Management

Q: A 59-year-old male with metastatic melanoma receiving combination ipilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks presents at Week 7 with severe diarrhea (8 watery bowel movements per day over baseline), severe crampy abdominal pain, and hematochezia (Grade 3 immune-mediated colitis). Diagnostic colonoscopy demonstrates extensive mucosal ulceration and friability. Stool PCR testing is negative for Clostridioides difficile, cytomegalovirus (CMV), and enteric bacterial pathogens. The patient is admitted and started on intravenous methylprednisolone 2 mg/kg/day. After 72 hours of high-dose intravenous corticosteroid therapy, the patient remains symptomatic with 7 to 8 bloody stools daily and persistent abdominal cramping. Which of the following represents the most appropriate next step in the clinical management of this patient?

Initiate Infliximab 5 mg/kg IV (or Vedolizumab 300 mg IV) as second-line biologic rescue while continuing systemic corticosteroids, repeating infliximab at 2 weeks if necessary.. According to ASCO, NCCN, and SITC guidelines, immune-mediated colitis that does not demonstrate clinical improvement within 48 to 72 hours of high-dose intravenous corticosteroids (methylprednisolone 1–2 mg/kg/day) is classified as steroid-refractory. The standard evidence-based second-line biologic rescue is Infliximab 5 mg/kg IV (TNF-alpha inhibitor), which may be repeated at Day 14 if needed. Alternatively, Vedolizumab 300 mg IV (an alpha4beta7 integrin inhibitor) provides gut-selective lymphocyte trafficking inhibition and is preferred if TNF-alpha blockade is contraindicated (e.g., active latent granulomatous infection, heart failure). Systemic corticosteroids must be continued and gradually tapered over >= 4–6 weeks once symptoms resolve. Mycophenolate is second-line for hepatitis, not colitis. Antimotility agents (loperamide) are contraindicated in severe inflammatory colitis due to the risk of toxic megacolon.

Q: A 62-year-old woman with metastatic non-small cell lung cancer receiving second-line pembrolizumab 200 mg IV every 3 weeks presents for routine laboratory monitoring prior to Cycle 4. She is completely asymptomatic, but laboratory results reveal an AST of 340 U/L (8.5x ULN), ALT of 410 U/L (10.2x ULN), and total bilirubin of 1.4 mg/dL (consistent with Grade 3 immune-mediated hepatitis). Viral hepatitis serologies (HAV, HBV, HCV, HEV, EBV, CMV) are negative, and hepatic ultrasound reveals no biliary obstruction. Pembrolizumab is held, and oral prednisone 1.5 mg/kg/day is initiated. Five days later, repeat liver function tests show worsening transaminitis (AST 395 U/L, ALT 480 U/L). Which of the following therapeutic interventions is CONTRAINDICATED in this patient, and what is the guideline-preferred second-line immunosuppressive agent?

Infliximab is contraindicated due to the risk of severe, fulminant hepatotoxicity and hepatic failure; the preferred agent is Mycophenolate Mofetil (MMF) 500–1000 mg orally/IV twice daily.. Infliximab carries a black box warning and strict contraindication for use in immune-mediated hepatitis because anti-TNF-alpha therapy can induce severe drug-induced liver injury (DILI) and precipitate acute fulminant hepatic necrosis. For steroid-refractory immune-mediated transaminitis (no improvement after 3–5 days of high-dose corticosteroids), the guideline-recommended second-line immunosuppressant is Mycophenolate Mofetil (MMF) 500 to 1000 mg PO/IV twice daily. In highly refractory cases, calcineurin inhibitors (tacrolimus) or anti-thymocyte globulin (ATG) may be considered.

Q: A 54-year-old male with metastatic clear cell renal cell carcinoma receiving frontline nivolumab 3 mg/kg plus ipilimumab 1 mg/kg presents at Week 12 with profound fatigue, anorexia, lightheadedness, and severe bitemporal headaches. Vital signs demonstrate orthostatic hypotension (blood pressure drops from 118/72 mmHg seated to 88/54 mmHg standing). Endocrine laboratory evaluation reveals: Morning serum cortisol 1.1 mcg/dL (low; reference 6–18), ACTH 3.8 pg/mL (low; reference 10–60), TSH 0.12 mIU/L (low; reference 0.4–4.5), Free T4 0.45 ng/dL (low; reference 0.8–1.8), and undetectable testosterone. Pituitary MRI demonstrates diffuse infundibular thickening and pituitary enlargement consistent with Grade 3 immune-mediated hypophysitis. What is the most appropriate initial and long-term pharmacotherapy plan?

Administer short-course systemic corticosteroids (e.g., oral prednisone 1 mg/kg/day or IV dexamethasone) for acute sellar mass effect/headache, followed by physiologic maintenance hydrocortisone (e.g., 20 mg AM, 10 mg PM) and levothyroxine replacement; resume checkpoint inhibitors once clinical stabilization is achieved.. Immune-mediated hypophysitis (more common with CTLA-4 inhibitors like ipilimumab) causes pituitary inflammation leading to secondary central adrenal insufficiency (low ACTH, low cortisol) and central hypothyroidism (low TSH, low free T4). In the acute phase with mass effect (severe headaches, visual field defects), short-term high-dose corticosteroids are indicated to reduce pituitary swelling. Once acute inflammation resolves, patients transition to lifelong physiological hormone replacement: Oral Hydrocortisone (15–25 mg daily in divided doses) and Levothyroxine. CRITICAL PEARL: Hydrocortisone MUST be started prior to or concurrently with levothyroxine, because initiating thyroid hormone in the setting of untreated adrenal insufficiency accelerates hepatic cortisol clearance and can precipitate fatal acute adrenal crisis. Unlike other Grade 3 irAEs, checkpoint inhibitors do NOT require permanent discontinuation for endocrinopathies once the patient is clinically stable on physiologic hormone replacement.

Q: A 67-year-old patient with metastatic urothelial carcinoma developing Grade 3 immune-mediated pneumonitis on avelumab is started on high-dose oral prednisone 1 mg/kg/day (70 mg daily) with a planned gradual taper over 8 weeks. What co-prescribed supportive medication is MANDATORY to prevent opportunistic pulmonary infection during this immunosuppressive taper, and when should it be initiated?

Trimethoprim-Sulfamethoxazole (TMP-SMX) 1 double-strength tablet orally three times weekly (or 1 single-strength tablet daily) for Pneumocystis jirovecii pneumonia (PJP) prophylaxis, initiated at the start of high-dose corticosteroid therapy.. Clinical practice guidelines (ASCO, NCCN, SITC, CDC) mandate Pneumocystis jirovecii pneumonia (PJP) prophylaxis for any oncology patient receiving the equivalent of prednisone >= 20 mg daily for >= 4 weeks. First-line prophylaxis is Trimethoprim-Sulfamethoxazole (TMP-SMX) 1 DS tablet orally three times weekly or 1 SS tablet orally once daily. PJP prophylaxis should be initiated at the start of high-dose corticosteroid therapy and continued throughout the steroid taper until the daily dose falls below 20 mg of prednisone equivalent. Alternative options in patients with severe sulfa allergy or G6PD deficiency include Dapsone 100 mg daily (after confirming normal G6PD enzyme activity), Atovaquone 1500 mg daily with a fatty meal, or monthly inhaled Pentamidine (300 mg).

Key Takeaways

Immune checkpoint inhibitors (ICIs) release negative regulatory brakes on T cells via distinct axes: CTLA-4 blockade (ipilimumab, tremelimumab) acts centrally in lymphoid tissue during naive T-cell priming, whereas PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, cemiplimab, dostarlimab; atezolizumab, avelumab, durvalumab) and LAG-3 inhibitors (relatlimab) act in peripheral tumor microenvironments to restore exhausted effector T-cell cytolytic function.
Predictive biomarker selection relies on standardized immunohistochemistry assays calculating Tumor Proportion Score (TPS), Combined Positive Score (CPS), or Immune Cell (IC) metrics, alongside tissue-agnostic approvals for high Microsatellite Instability (MSI-H / dMMR) and Tumor Mutational Burden (TMB-High >= 10 mut/Mb).
Immune-related adverse events (irAEs) follow an organ-specific chronological emergence: dermatologic (2–4 weeks) -> gastrointestinal/colitis (6–8 weeks) -> hepatic (8–12 weeks) -> endocrinopathies (12–24 weeks) -> pulmonary and rare life-threatening myocarditis/neuropathies.
Standard irAE pharmacotherapy mandates immediate high-dose corticosteroids (prednisone 1–2 mg/kg/day or IV methylprednisolone equivalent) for Grade >= 2 toxicities with an extended taper over >= 4 to 6 weeks, paired with mandatory Pneumocystis jirovecii pneumonia (PJP) prophylaxis with TMP-SMX when prednisone is >= 20 mg/day equivalent for >= 4 weeks.
Steroid-refractory irAE algorithms require target-specific biologics: Infliximab (5 mg/kg) or Vedolizumab (300 mg) for colitis, Mycophenolate Mofetil (500–1000 mg BID) for hepatitis (INFLIXIMAB IS STRICTLY CONTRAINDICATED in hepatitis due to hepatic failure risk), and early Pulse Methylprednisolone (1,000 mg/day) plus Abatacept or Alemtuzumab for life-threatening immune-mediated myocarditis.

Last updated: August 2026

7.1 Immune Checkpoint Inhibitors & irAE Management

Immune Checkpoint Inhibitors (ICIs) have revolutionized the therapeutic landscape of modern clinical oncology. Rather than targeting oncogenic driver mutations within neoplastic cells, ICIs harness the host's endogenous adaptive immune system by disrupting inhibitory co-signaling pathways that tumors exploit to escape immunosurveillance. By blocking Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4), Programmed Cell Death Protein 1 (PD-1), Programmed Death-Ligand 1 (PD-L1), or Lymphocyte Activation Gene 3 (LAG-3), these monoclonal antibodies unleash tumor-reactive cytotoxic T lymphocytes (CD8+ CTLs) to induce durable clinical remissions.

However, disinhibiting self-tolerance mechanisms precipitates a distinct spectrum of autoimmune toxicities termed immune-related adverse events (irAEs). Oncology clinical pharmacists play an indispensable role in biomarker stratification, regimen selection, early toxicity interception, steroid tapering protocols, and second-line biologic rescue management.

1. Immunology & Mechanisms of Immune Checkpoint Pathways

T-cell activation is tightly regulated by a two-signal model. Signal 1 involves the binding of the T-Cell Receptor (TCR) to a specific peptide presented by the Major Histocompatibility Complex (MHC) on an Antigen-Presenting Cell (APC) or tumor cell. Signal 2 consists of costimulatory or coinhibitory interactions between receptor-ligand pairs that determine whether the T cell undergoes clonal proliferation or functional inactivation (anergy/exhaustion).

+-----------------------------------------------------------------------------+
|              IMMUNE CHECKPOINT PATHWAYS: PRIMING VS. EFFECTOR PHASES         |
|                                                                             |
|   [CENTRAL LYMPHOID PRIMING PHASE]          [PERIPHERAL EFFECTOR PHASE]     |
|   (Antigen-Presenting Cell <-> Naive T Cell) (Tumor Cell <-> Cytotoxic T Cell)|
|                                                                             |
|         APC                 T Cell                Tumor             T Cell   |
|    +-----------+        +-----------+         +-----------+     +-----------+|
|    |  MHC-Ag   | ------>|    TCR    |         |  MHC-Ag   |---->|    TCR    ||
|    +-----------+        +-----------+         +-----------+     +-----------+|
|                                                                             |
|    +-----------+        +-----------+         +-----------+     +-----------+|
|    | B7-1/B7-2 | --+    |   CD28    |         |   PD-L1   |     |   PD-1    ||
|    | (CD80/86) |   |    | (Costim)  |         |   PD-L2   |--X--| (Inhibit) ||
|    +-----------+   |    +-----------+         +-----------+  |  +-----------+|
|          |         |                                         |       |      |
|          |         |    +-----------+                        |   [SHP-1/2]  |
|          +----X----+    |  CTLA-4   |                        |   Dephospho- |
|               |         | (Inhibit) |                        |   rylates TCR|
|               |         +-----------+                        |              |
|        [IPILIMUMAB /         |                        [PEMBRO / NIVO /      |
|         TREMELIMUMAB]   High-affinity                  CEMIP / DOSTAR]      |
|         Blocks CTLA-4   B7 competitive                                      |
|         sequestration   outcompeting CD28             [ATEZO / AVELU /      |
|                                                        DURVA] Blocks PD-L1  |
+-----------------------------------------------------------------------------+

Distinct Biological Checkpoint Axes

CTLA-4 Axis (Central Tolerance & Priming):
- Expressed exclusively on T cells (and constitutively on immunosuppressive Regulatory T cells [Tregs]).
- Following TCR stimulation, CTLA-4 is mobilized from intracellular vesicles to the cell surface, where it binds CD80 (B7-1) and CD86 (B7-2) with 20- to 100-fold higher affinity than the costimulatory receptor CD28.
- CTLA-4 outcompetes CD28, transmitting direct inhibitory signals and physically removing B7 ligands via trans-endocytosis, thereby terminating naive T-cell priming within secondary lymphoid organs.
- Therapeutic Agents: Ipilimumab (fully human IgG1 mAb) and Tremelimumab (fully human IgG4 mAb). Dual mechanism: blocks CTLA-4 co-inhibition and mediates selective depletion of intratumoral Tregs via antibody-dependent cellular cytotoxicity (ADCC).
PD-1 / PD-L1 Axis (Peripheral Tolerance & Effector Phase):
- Expressed on activated T cells, B cells, NK cells, and tumor-infiltrating lymphocytes upon chronic antigen exposure.
- Binds PD-L1 (B7-H1 / CD274) and PD-L2 (B7-DC / CD273) expressed on tumor cells, macrophages, and parenchymal tissue in response to inflammatory cytokines (especially IFN-gamma).
- Engagement of PD-1 recruits SHP-2 (Src homology 2 domain-containing protein tyrosine phosphatase 2) to its cytoplasmic immunoreceptor tyrosine-based switch motif (ITSM), dephosphorylating proximal TCR signaling kinases (ZAP70, CD3-zeta) and blocking PI3K-AKT-mTOR activation, inducing T-cell exhaustion.
- Anti-PD-1 Monoclonal Antibodies: Pembrolizumab (humanized IgG4), Nivolumab (fully human IgG4), Cemiplimab (fully human IgG4), Dostarlimab (humanized IgG4).
- Anti-PD-L1 Monoclonal Antibodies: Atezolizumab (engineered Fc-null humanized IgG1), Avelumab (fully human IgG1 capable of inducing ADCC via NK cells), Durvalumab (engineered human IgG1 with reduced Fc effector function).
LAG-3 Axis (Lymphocyte Activation Gene 3 / CD223):
- Co-inhibitory receptor structurally homologous to CD4, expressed on exhausted CD4+ and CD8+ T cells, Tregs, and NK cells.
- Binds MHC Class II molecules with significantly higher affinity than CD4, delivering negative signals that arrest cell cycle progression and cytokine production.
- Therapeutic Agent: Relatlimab (fully human IgG4 mAb co-formulated with nivolumab as Opdualag). Demonstrated superior progression-free survival over nivolumab monotherapy in the pivotal Phase 3 RELATIVITY-047 trial in untreated metastatic melanoma (median PFS 10.1 vs. 4.6 months; HR 0.75, p = 0.0055).

Master FDA-Approved Immune Checkpoint Inhibitor Reference

Generic Name	Target	Antibody Isotype	Landmark Clinical Indications	Key Dosing Regimens
Pembrolizumab	PD-1	Humanized IgG4-kappa	Melanoma, NSCLC, HNSCC, Classical Hodgkin Lymphoma, Urothelial, MSI-H/dMMR Solid Tumors, TMB-H, TNBC, Cervical, Gastric/GEJ, RCC	200 mg IV Q3W OR 400 mg IV Q6W (30-minute IV infusion)
Nivolumab	PD-1	Fully Human IgG4-kappa	Melanoma (+/- Ipilimumab or Relatlimab), NSCLC (+/- Ipi/chemo), RCC (+/- Ipi or Cabozantinib), Classical Hodgkin, Urothelial, HCC, CRC (MSI-H), Esophageal	240 mg IV Q2W OR 480 mg IV Q4W (30-minute IV infusion)
Cemiplimab	PD-1	Fully Human IgG4	Cutaneous Squamous Cell Carcinoma (CSCC), Basal Cell Carcinoma (BCC), NSCLC	350 mg IV Q3W (30-minute IV infusion)
Dostarlimab	PD-1	Humanized IgG4-kappa	dMMR Endometrial Cancer, dMMR/MSI-H Recurrent/Advanced Solid Tumors, Locally Advanced dMMR Rectal Cancer (neoadjuvant single-agent)	500 mg IV Q3W x 4 doses, then 1,000 mg IV Q6W
Atezolizumab	PD-L1	Engineered Humanized IgG1	Extensive-Stage SCLC (+ Carboplatin/Etoposide), Hepatocellular Carcinoma (+ Bevacizumab), Alveolar Soft Part Sarcoma, Adjuvant NSCLC	840 mg IV Q2W, 1,200 mg IV Q3W, or 1,680 mg IV Q4W
Durvalumab	PD-L1	Engineered Human IgG1-kappa	Unresectable Stage III NSCLC post-chemoradiation (PACIFIC), Extensive-Stage SCLC (CASPIAN), Biliary Tract Cancer (TOPAZ-1), Endometrial	10 mg/kg IV Q2W or 1,500 mg IV Q4W (fixed dose for body weight >= 30 kg)
Avelumab	PD-L1	Fully Human IgG1 (ADCC-competent)	Merkel Cell Carcinoma, Urothelial Carcinoma (maintenance post-platinum per JAVELIN Bladder 100), Advanced RCC (+ Axitinib)	800 mg IV Q2W (60-minute infusion; premedicate with antihistamine/acetaminophen)
Ipilimumab	CTLA-4	Fully Human IgG1-kappa	Metastatic Melanoma (+/- Nivolumab), Advanced RCC (+ Nivolumab), Metastatic CRC (MSI-H, + Nivolumab), NSCLC (+ Nivolumab), Malignant Pleural Mesothelioma	3 mg/kg IV Q3W (Melanoma combo) or 1 mg/kg IV Q6W (NSCLC/RCC combo)
Tremelimumab	CTLA-4	Fully Human IgG4-kappa	Unresectable Hepatocellular Carcinoma (STRIDE regimen: single 300 mg priming dose + Durvalumab), Metastatic NSCLC (+ Durvalumab + Chemo)	300 mg IV single dose (HCC) or 75 mg IV Q3W x 5 doses (NSCLC)
Relatlimab (+ Nivolumab)	LAG-3 (+ PD-1)	Fully Human IgG4	Treatment-naive Unresectable or Metastatic Melanoma (RELATIVITY-047)	Fixed-dose combo: Relatlimab 160 mg + Nivolumab 480 mg IV Q4W

2. Predictive Biomarkers & Patient Selection

Patient response to immune checkpoint inhibition is heterogeneous. Precision immunotherapy relies on validated predictive biomarkers to optimize clinical benefit and avoid unnecessary toxicity.

+-----------------------------------------------------------------------------+
|                     PREDICTIVE BIOMARKER INTERPRETATION                     |
|                                                                             |
|   [PD-L1 IHC SCORING]                                                       |
|   - TPS (Tumor Proportion Score): % viable tumor cells with membrane PD-L1  |
|     * Used in: NSCLC (Pembrolizumab monotherapy requires TPS >= 1% or >=50%)|
|   - CPS (Combined Positive Score):                                          |
|     [ # PD-L1 staining cells (Tumor + Lymphocytes + Macrophages) ]          |
|     -------------------------------------------------------------- x 100    |
|                         Total Viable Tumor Cells                            |
|     * Used in: Gastric/GEJ (CPS >= 5), HNSCC (CPS >= 1), TNBC (CPS >= 10),   |
|       Cervical (CPS >= 1), Esophageal Adeno/Squamous (CPS >= 10)            |
|                                                                             |
|   [TISSUE-AGNOSTIC GENOMIC BIOMARKERS]                                      |
|   - MSI-H / dMMR: Loss of MLH1, MSH2, MSH6, or PMS2 via IHC; high-frequency |
|     microsatellite instability via PCR/NGS -> Hypermutated neoantigens      |
|   - TMB-H (Tumor Mutational Burden-High): >= 10 mutations/megabase (mut/Mb) |
|     via FDA-approved NGS test (FoundationOne CDx)                           |
+-----------------------------------------------------------------------------+

Biomarker Testing Details for BCOP

PD-L1 Expression Testing & Antibody Clones:
- 22C3 PharmDx (Dako): Companion diagnostic for pembrolizumab in NSCLC (TPS >= 1% or >= 50%), gastric/GEJ (CPS >= 5), HNSCC (CPS >= 1 or >= 20), TNBC (CPS >= 10), and cervical cancer (CPS >= 1).
- 28-8 PharmDx (Dako): Complementary diagnostic for nivolumab (melanoma, NSCLC, RCC, bladder).
- SP263 (Ventana): Diagnostic for durvalumab (NSCLC) and pembrolizumab cross-indication.
- SP142 (Ventana): Historically utilized for atezolizumab; measures PD-L1 on tumor-infiltrating immune cells (IC score).
Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR):
- Defective DNA Mismatch Repair enzymes (MLH1, MSH2, MSH6, PMS2) result in the accumulation of thousands of somatic insertion/deletion mutations across repetitive DNA tracts (microsatellites).
- Generates massive numbers of immunogenic frameshift neoantigens, attracting dense tumor-infiltrating lymphocytes (TILs) and rendering tumors exceptionally sensitive to PD-1 blockade regardless of primary tissue origin.
- Milestone: In 2017, the FDA granted the first tissue-agnostic approval in history to pembrolizumab for any unresectable or metastatic MSI-H/dMMR solid tumor progressing after prior therapy (expanded to dostarlimab in 2021).
Tumor Mutational Burden (TMB-High):
- Defined as >= 10 mutations per megabase (mut/Mb) determined by an FDA-approved comprehensive genomic profiling NGS assay.
- High somatic mutation density increases the statistical probability of generating MHC-presented neoepitopes recognized as non-self by host CD8+ T cells.
Pseudoprogression vs. Hyperprogression:
- Pseudoprogression: Transient initial increase in total tumor burden or appearance of new radiographic lesions caused by dense intratumoral infiltration of cytotoxic lymphocytes and local edema, followed by durable tumor regression. Evaluated clinically using iRECIST (Immune-modified Response Evaluation Criteria in Solid Tumors); requires confirmation of disease progression on repeat imaging 4–8 weeks later in clinically stable patients.
- Hyperprogression: Dramatic, fulminant acceleration of tumor growth kinetics (>2-fold increase in tumor growth rate) following ICI initiation, frequently associated with MDM2/MDM4 amplifications or EGFR aberrations. Requires immediate cessation of ICI and switch to cytotoxic chemotherapy.

3. irAE Pathophysiology, Grading & General Management Principles

Unlike conventional chemotherapy-induced cytotoxic myelosuppression or targeted kinase inhibitor toxicities, irAEs are autoimmune in etiology. They result from the systemic activation of autoreactive T-cell clones, increased production of pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha, IFN-gamma), and the generation of de novo autoantibodies against healthy host tissues.

+-----------------------------------------------------------------------------+
|                       CHRONOLOGICAL ONSET OF irAEs                          |
|                                                                             |
|   WEEKS:  0      2      4      6      8      10     12     16     20    24  |
|           |------|------|------|------|------|------|------|------|------|  |
|   SKIN    [==== Rash / Pruritus / Vitiligo ==================>]             |
|   GI             [==== Colitis / Diarrhea ======>]                          |
|   LIVER                 [==== Transaminitis / Hepatitis ====>]              |
|   PULMONARY                    [==== Pneumonitis ============>]             |
|   ENDOCRINE                           [==== Hypophysitis / Thyroiditis ====>|
|   NEURO/CARDIAC  [<-- Can occur unpredictably at ANY time; early vigilance] |
+-----------------------------------------------------------------------------+

General irAE Severity Grading & Action Guidelines

+-----------------------------------------------------------------------------+
|                   ASCO / NCCN / SITC irAE GRADING & ACTION                  |
|                                                                             |
|   GRADE 1 (Mild):                                                           |
|   - Asymptomatic or mild symptoms; clinical or diagnostic observations only |
|   - ACTION: Continue ICI in most cases; close monitoring; symptomatic care  |
|     (Exceptions: Neurologic, hematologic, or cardiac toxicities mandate hold)|
|                                                                             |
|   GRADE 2 (Moderate):                                                       |
|   - Moderate symptoms; minimal, local, or non-invasive intervention indicated|
|   - ACTION: Withhold ICI; start Oral Prednisone 0.5-1 mg/kg/day (or equiv); |
|     taper over >= 4-6 weeks once resolved to Grade <= 1; resume when <= G1  |
|                                                                             |
|   GRADE 3 (Severe / Medically Significant):                                 |
|   - Severe symptoms; hospitalization indicated; limiting self-care ADLs     |
|   - ACTION: Permanently discontinue ICI (or withhold select cases); start   |
|     High-Dose IV Methylprednisolone 1-2 mg/kg/day; taper over >= 4-6 weeks  |
|                                                                             |
|   GRADE 4 (Life-Threatening):                                               |
|   - Urgent intervention indicated; life-threatening consequences            |
|   - ACTION: PERMANENTLY DISCONTINUE ICI; start IV Methylprednisolone 1-2    |
|     mg/kg/day or Pulse 1,000 mg/day (myocarditis/CNS); escalate to biologics|
+-----------------------------------------------------------------------------+

4. Organ-Specific irAE Management Protocols

+-----------------------------------------------------------------------------+
|               ORGAN-SPECIFIC irAE MASTER PHARMACOTHERAPY MATRIX             |
+-----------------------------------------------------------------------------+
| 1. IMMUNE-MEDIATED COLITIS / ENTERITIS                                      |
|    - Definition: Grade 2 (4-6 stools/day over baseline), Grade 3 (>=7/day)  |
|    - Workup: Stool C. diff PCR, multiplex viral/bacterial panel, lactoferrin|
|    - First-Line: IV Methylprednisolone 1-2 mg/kg/day or PO Prednisone 1 mg/kg|
|    - Steroid-Refractory (No improvement within 48-72 hours):                |
|      * INFLIXIMAB 5 mg/kg IV at Weeks 0 and 2 (Avoid if perforation/sepsis) |
|      * VEDOLIZUMAB 300 mg IV (alpha4beta7 integrin inhibitor; gut-selective)|
|-----------------------------------------------------------------------------|
| 2. IMMUNE-MEDIATED HEPATITIS (TRANSAMINITIS)                                |
|    - Definition: G2 (AST/ALT 3-5x ULN), G3 (AST/ALT >5-20x ULN)             |
|    - First-Line: Hold/discontinue ICI; Methylprednisolone 1-2 mg/kg/day     |
|    - CRITICAL PHARMACY CONTRAINDICATION: INFLIXIMAB IS CONTRAINDICATED      |
|      due to high risk of precipitating acute fulminant hepatic failure!     |
|    - Steroid-Refractory Rescue: MYCOPHENOLATE MOFETIL (MMF) 500-1000 mg PO/IV|
|      Q12H +/- Tacrolimus (target trough 5-10 ng/mL)                         |
|-----------------------------------------------------------------------------|
| 3. IMMUNE-MEDIATED PNEUMONITIS                                              |
|    - Definition: G1 (radiographic only), G2 (dyspnea, cough), G3/4 (hypoxia)|
|    - Workup: Chest CT (ground glass, organizing pneumonia), bronchoscopy/BAL|
|    - First-Line: G2 -> PO Prednisone 1-2 mg/kg/day; G3/4 -> IV Methylpred   |
|      2-4 mg/kg/day; taper slowly over >= 6 weeks                            |
|    - Refractory: Infliximab 5 mg/kg, IVIG (2 g/kg over 2-5 days), or MMF    |
|-----------------------------------------------------------------------------|
| 4. IMMUNE-MEDIATED ENDOCRINOPATHIES                                         |
|    - Hypophysitis: Low ACTH, low cortisol, low TSH, low Free T4, headache   |
|      * Acute phase: High-dose steroids for mass effect/chiasm compression   |
|      * Replacement: Hydrocortisone 20 mg AM / 10 mg PM + Levothyroxine      |
|    - Thyroiditis: Transient hyperthyroidism (propranolol) -> Permanent      |
|      Hypothyroidism. Treat with LEVOTHYROXINE; DO NOT STOP ICI THERAPY!     |
|    - Type 1 Diabetes: Acute DKA; permanent insulin therapy; resume ICI      |
|-----------------------------------------------------------------------------|
| 5. IMMUNE-MEDIATED MYOCARDITIS (MORTALITY 30-50%)                           |
|    - Signs: Elevated high-sensitivity Troponin, ECG conduction block, drop  |
|      in LVEF, ventricular arrhythmias, pericardial effusion                 |
|    - ACTION: Immediate permanent ICI cessation; ICU admission;              |
|      PULSE METHYLPREDNISOLONE 1,000 mg IV daily x 3-5 days                  |
|    - Early Biologic Escalation (within 24h if troponin not clearing):       |
|      * ABATACEPT (CTLA-4-Ig agonist): 500-1000 mg IV at Day 1, 3, 7, 14     |
|      * ALEMTUZUMAB (Anti-CD52): 30 mg IV single dose (depletes T cells)     |
|      * Second-Line: Infliximab, Mycophenolate Mofetil, Tofacitinib, ATG     |
|-----------------------------------------------------------------------------|
| 6. IMMUNE-MEDIATED NEUROTOXICITIES                                          |
|    - Spectrum: Myasthenia Gravis (MG), Guillain-Barré Syndrome (GBS),       |
|      Aseptic Meningitis, Autoimmune Encephalitis                            |
|    - Management: Discontinue ICI; Methylprednisolone 1-2 mg/kg/day;         |
|      IVIG (0.4 g/kg/day x 5 days [total 2 g/kg]) OR Plasmapheresis (PLEX)   |
|    - MG Specific: Pyridostigmine 30-60 mg PO TID. AVOID beta-blockers,      |
|      IV magnesium, fluoroquinolones, macrolides (worsen neuromuscular block)|
+-----------------------------------------------------------------------------+

[!CAUTION] Steroid-Refractory Hepatitis vs. Infliximab Warning: Board examinations frequently test the management of steroid-refractory transaminitis. While infliximab is the gold standard for steroid-refractory colitis, infliximab is strictly contraindicated in immune-mediated hepatitis due to its known potential to induce autoimmune drug-induced liver injury (DILI) and fulminant hepatic necrosis. The correct steroid-refractory rescue agent for hepatitis is Mycophenolate Mofetil (MMF).

5. Pharmacist-Led Immunosuppression Safety & Antimicrobial Prophylaxis

High-dose, prolonged corticosteroid therapy introduces substantial risks of opportunistic infections, metabolic derangements, and secondary adrenal insufficiency.

+-----------------------------------------------------------------------------+
|               PHARMACIST PROTOCOL FOR HIGH-DOSE CORTICOSTEROIDS             |
|                                                                             |
|   1. PNEUMOCYSTIS JIROVECII PNEUMONIA (PJP) PROPHYLAXIS                     |
|      - MANDATORY Criteria: Prednisone >= 20 mg/day equivalent for >= 4 weeks|
|      - First-Line: Trimethoprim-Sulfamethoxazole (TMP-SMX) 1 DS tab PO 3x/wk|
|        OR 1 SS tab PO daily                                                 |
|      - Alternative (Sulfa-Allergy / G6PD Deficiency):                       |
|        * Dapsone 100 mg PO daily (Must verify normal G6PD baseline)         |
|        * Atovaquone 1500 mg PO daily with meals                             |
|        * Inhaled Pentamidine 300 mg monthly via Respirgard II nebulizer     |
|                                                                             |
|   2. GASTROPROTECTION & BONE HEALTH                                         |
|      - PPI (Pantoprazole 40 mg daily) or H2RA during high-dose steroids     |
|      - Calcium 1000-1200 mg/day + Vitamin D 800-1000 IU/day                 |
|                                                                             |
|   3. STEROID TAPERING RULES                                                 |
|      - NEVER taper faster than over 4 to 6 weeks (often 6-8 weeks required) |
|      - Rapid tapering (<3 weeks) results in severe rebound irAE flares!     |
|      - Taper schedule: Reduce by 10 mg/week until 20 mg daily, then by      |
|        5 mg/week, assessing clinical symptoms before each step-down         |
+-----------------------------------------------------------------------------+

Re-challenging with Checkpoint Inhibitors Post-irAE

Permanent Discontinuation (Never Re-challenge): Any Grade 4 toxicity, Grade >= 2 myocarditis, Grade >= 3 neurotoxicity (myasthenia gravis, encephalitis, Guillain-Barré), Grade 3/4 pneumonitis, Grade >= 3 Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis (SJS/TEN), or recurrent severe Grade 3 irAEs.
Permissible Re-challenge: Grade 2 or select Grade 3 organ toxicities (e.g., colitis, transaminitis) that completely resolve to Grade <= 1 and patient is tapered to prednisone <= 10 mg/day equivalent. Switching from dual-agent (ipilimumab + nivolumab) to anti-PD-1 monotherapy is commonly employed with careful pharmacovigilance.

Test Your Knowledge

A 59-year-old male with metastatic melanoma receiving combination ipilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks presents at Week 7 with severe diarrhea (8 watery bowel movements per day over baseline), severe crampy abdominal pain, and hematochezia (Grade 3 immune-mediated colitis). Diagnostic colonoscopy demonstrates extensive mucosal ulceration and friability. Stool PCR testing is negative for Clostridioides difficile, cytomegalovirus (CMV), and enteric bacterial pathogens. The patient is admitted and started on intravenous methylprednisolone 2 mg/kg/day. After 72 hours of high-dose intravenous corticosteroid therapy, the patient remains symptomatic with 7 to 8 bloody stools daily and persistent abdominal cramping. Which of the following represents the most appropriate next step in the clinical management of this patient?

Initiate Infliximab 5 mg/kg IV (or Vedolizumab 300 mg IV) as second-line biologic rescue while continuing systemic corticosteroids, repeating infliximab at 2 weeks if necessary.

Switch immediately to Mycophenolate Mofetil 1,000 mg IV every 12 hours, as anti-TNF-alpha agents are strictly contraindicated in immune-mediated gastrointestinal toxicity.

Add high-dose oral loperamide 4 mg every 2 hours and resume nivolumab monotherapy at a reduced dose.

Perform immediate emergency total colectomy with end ileostomy, as corticosteroid failure indicates irreversible transmural bowel infarction.

Test Your Knowledge

A 62-year-old woman with metastatic non-small cell lung cancer receiving second-line pembrolizumab 200 mg IV every 3 weeks presents for routine laboratory monitoring prior to Cycle 4. She is completely asymptomatic, but laboratory results reveal an AST of 340 U/L (8.5x ULN), ALT of 410 U/L (10.2x ULN), and total bilirubin of 1.4 mg/dL (consistent with Grade 3 immune-mediated hepatitis). Viral hepatitis serologies (HAV, HBV, HCV, HEV, EBV, CMV) are negative, and hepatic ultrasound reveals no biliary obstruction. Pembrolizumab is held, and oral prednisone 1.5 mg/kg/day is initiated. Five days later, repeat liver function tests show worsening transaminitis (AST 395 U/L, ALT 480 U/L). Which of the following therapeutic interventions is CONTRAINDICATED in this patient, and what is the guideline-preferred second-line immunosuppressive agent?

Mycophenolate mofetil is contraindicated due to renal elimination; the preferred agent is high-dose IVIG 2 g/kg over 2 days.

Infliximab is contraindicated due to the risk of severe, fulminant hepatotoxicity and hepatic failure; the preferred agent is Mycophenolate Mofetil (MMF) 500–1000 mg orally/IV twice daily.

Tacrolimus is contraindicated due to microangiopathic hemolytic anemia; the preferred agent is Vedolizumab 300 mg IV infusion.

Intravenous corticosteroid pulse therapy is contraindicated; the preferred agent is immediate resumption of pembrolizumab with oral ursodiol.

Test Your Knowledge

A 54-year-old male with metastatic clear cell renal cell carcinoma receiving frontline nivolumab 3 mg/kg plus ipilimumab 1 mg/kg presents at Week 12 with profound fatigue, anorexia, lightheadedness, and severe bitemporal headaches. Vital signs demonstrate orthostatic hypotension (blood pressure drops from 118/72 mmHg seated to 88/54 mmHg standing). Endocrine laboratory evaluation reveals: Morning serum cortisol 1.1 mcg/dL (low; reference 6–18), ACTH 3.8 pg/mL (low; reference 10–60), TSH 0.12 mIU/L (low; reference 0.4–4.5), Free T4 0.45 ng/dL (low; reference 0.8–1.8), and undetectable testosterone. Pituitary MRI demonstrates diffuse infundibular thickening and pituitary enlargement consistent with Grade 3 immune-mediated hypophysitis. What is the most appropriate initial and long-term pharmacotherapy plan?

Permanently discontinue all checkpoint inhibitors, administer Infliximab 5 mg/kg IV, and initiate high-dose radioactive iodine ablation.

Initiate full-dose Levothyroxine 1.6 mcg/kg daily immediately; withhold all corticosteroid therapy until free T4 levels completely normalize.

Administer short-course systemic corticosteroids (e.g., oral prednisone 1 mg/kg/day or IV dexamethasone) for acute sellar mass effect/headache, followed by physiologic maintenance hydrocortisone (e.g., 20 mg AM, 10 mg PM) and levothyroxine replacement; resume checkpoint inhibitors once clinical stabilization is achieved.

Administer fludrocortisone 0.1 mg daily as monotherapy, as isolated mineralocorticoid deficiency is the primary hormonal defect in autoimmune hypophysitis.

Test Your Knowledge

A 67-year-old patient with metastatic urothelial carcinoma developing Grade 3 immune-mediated pneumonitis on avelumab is started on high-dose oral prednisone 1 mg/kg/day (70 mg daily) with a planned gradual taper over 8 weeks. What co-prescribed supportive medication is MANDATORY to prevent opportunistic pulmonary infection during this immunosuppressive taper, and when should it be initiated?

Fluconazole 400 mg daily for invasive aspergillosis prophylaxis, initiated only when the prednisone dose drops below 20 mg daily.

Valganciclovir 900 mg daily for cytomegalovirus reactivation, initiated on Day 1 of high-dose corticosteroids.

Inhaled Tobramycin 300 mg twice daily for Pseudomonas colonization, initiated after 14 days of corticosteroid therapy.

Trimethoprim-Sulfamethoxazole (TMP-SMX) 1 double-strength tablet orally three times weekly (or 1 single-strength tablet daily) for Pneumocystis jirovecii pneumonia (PJP) prophylaxis, initiated at the start of high-dose corticosteroid therapy.

Up Next

7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers

Continue learning

BCOP Board Certified Oncology Pharmacist

BCOP Board Certified Oncology Pharmacist

7.1 Immune Checkpoint Inhibitors & irAE Management

Key Takeaways

7.1 Immune Checkpoint Inhibitors & irAE Management

1. Immunology & Mechanisms of Immune Checkpoint Pathways

Distinct Biological Checkpoint Axes

Master FDA-Approved Immune Checkpoint Inhibitor Reference

2. Predictive Biomarkers & Patient Selection

Biomarker Testing Details for BCOP

3. irAE Pathophysiology, Grading & General Management Principles

General irAE Severity Grading & Action Guidelines

4. Organ-Specific irAE Management Protocols

5. Pharmacist-Led Immunosuppression Safety & Antimicrobial Prophylaxis

Re-challenging with Checkpoint Inhibitors Post-irAE

BCOP Board Certified Oncology Pharmacist

1Chapter 1: Introduction & BCOP Exam Foundations

2Chapter 2: Cancer Biology & Pathophysiology

3Chapter 3: Genomic Biomarkers & Molecular Targets

4Chapter 4: Diagnostics, Staging & Clinical Assessment

5Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens

6Chapter 6: Targeted Small-Molecule Therapies

7Chapter 7: Immunotherapy, Biologics & Cellular Therapy

8Chapter 8: Breast & Gynecologic Malignancies

9Chapter 9: Thoracic & Skin Malignancies

10Chapter 10: Gastrointestinal & Genitourinary Malignancies

11Chapter 11: Hematologic Malignancies: Leukemias & Myeloma

12Chapter 12: Lymphomas & Stem Cell Transplantation

13Chapter 13: Supportive Care & Toxicity Management

14Chapter 14: Hazardous Drug Handling & Compounding Safety

15Chapter 15: Chemotherapy Safety, Dosing & Order Verification

16Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation

17Chapter 17: Health Systems, Regulatory Compliance & Patient Education

BCOP Board Certified Oncology Pharmacist

7.1 Immune Checkpoint Inhibitors & irAE Management

Key Takeaways

7.1 Immune Checkpoint Inhibitors & irAE Management

1. Immunology & Mechanisms of Immune Checkpoint Pathways

Distinct Biological Checkpoint Axes

Master FDA-Approved Immune Checkpoint Inhibitor Reference

2. Predictive Biomarkers & Patient Selection

Biomarker Testing Details for BCOP

3. irAE Pathophysiology, Grading & General Management Principles

General irAE Severity Grading & Action Guidelines

4. Organ-Specific irAE Management Protocols

5. Pharmacist-Led Immunosuppression Safety & Antimicrobial Prophylaxis

Re-challenging with Checkpoint Inhibitors Post-irAE